APA (7th ed.) Citation

R, P., MH, S., R, H., BM, R., N, R., JP, N., . . . NA, H. (2025). TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumors. Cell reports. Medicine, 6(4), 102041. https://doi.org/10.1016/j.xcrm.2025.102041

Chicago Style (17th ed.) Citation

R, Plummer, et al. "TIMEPOINT, a Phase 1 Study Combining MTL-CEBPA with Pembrolizumab, Supports the Immunomodulatory Effect of MTL-CEBPA in Solid Tumors." Cell Reports. Medicine 6, no. 4 (2025): 102041. https://doi.org/10.1016/j.xcrm.2025.102041.

MLA (9th ed.) Citation

R, Plummer, et al. "TIMEPOINT, a Phase 1 Study Combining MTL-CEBPA with Pembrolizumab, Supports the Immunomodulatory Effect of MTL-CEBPA in Solid Tumors." Cell Reports. Medicine, vol. 6, no. 4, 2025, p. 102041, https://doi.org/10.1016/j.xcrm.2025.102041.